Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer-Reference-Cited by-同舟云学术

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer

Published:2019-01-25 Issue:4 Volume:83 Page:763-774
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Hoemme Alexander,Barth Holger,Haschke Manuel,Krähenbühl Stephan,Strasser Florian,Lehner Claudia,von Kameke Alexander,Wälti Thomas,Thürlimann Beat,Früh Martin,Driessen Christoph,Joerger Markus^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-019-03783-9/fulltext.html

Reference35 articles.

1. Beijnen JH, Schellens JH (2004) Drug interactions in oncology. Lancet Oncol 5(8):489–496. https://doi.org/10.1016/S1470-2045(04)01528-1

2. Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6(7):546–558. https://doi.org/10.1038/nrc1887

3. McLeod HL (1997) Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 74(1):39–54

4. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263–275

5. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Med 13:74. https://doi.org/10.1186/s12916-015-0322-7

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital;Cureus;2024-05-17

2. Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade;Cancers;2024-01-20

3. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies;Thrombosis Research;2023-11

4. Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study;Current Drug Safety;2023-05

5. TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer;Journal of Cancer Research and Clinical Oncology;2023-03-06